Currently Viewing:
The American Journal of Managed Care August 2010
Clinical and Economic Outcomes After Introduction of Drug-Eluting Stents
Charanjit S. Rihal, MD, MBA; James L. Ryan, MHA; Mandeep Singh, MBBS; Ryan J. Lennon, MS; John F. Bresnahan, MD; Juliette T. Liesinger, BA; Bernard J. Gersh, MBChB, DPhil; Henry H. Ting, MD, MBA; David R. Holmes, Jr, MD; and Kirsten Hall Long, PhD
Antihypertensive Medication Adherence and Subsequent Healthcare Utilization and Costs
Donald G. Pittman, PharmD; Zhuliang Tao, MPH; William Chen, PhD; and Glen D. Stettin, MD
Statin Therapy for Elevated hsCRP: What Are the Public Health Implications?
Paul M. Ridker, MD
Statin Therapy for Elevated hsCRP: More Evidence Is Needed
Ogochukwu C. Molokwu, PharmD, MScMed
Opening and Continuing the Discussion on Influenza Vaccination Timing
Kellie J. Ryan, MPH Matthew D. Rousculp, PhD, MPH. Reply by Bruce Y. Lee, MD, MBA Julie H. Y. Tai, MD Rachel R. Bailey, MPH
Cost Sharing, Adherence, and Health Outcomes in Patients With Diabetes
Teresa B. Gibson, PhD; Xue Song, PhD; Berhanu Alemayehu, DrPH; Sara S. Wang, PhD; Jessica L. Waddell, MPH; Jonathan R. Bouchard, MS, RPh; and Felicia Forma, BSc
Relationship Between Quality Improvement Processes and Clinical Performance
Cheryl L. Damberg, PhD; Stephen M. Shortell, PhD, MPH, MBA; Kristiana Raube, PhD, MPH; Robin R. Gillies, PhD; Diane Rittenhouse, MD, MPH; Rodney K. McCurdy, MHA; Lawrence P. Casalino, MD, PhD; and John Adams, PhD
Value and the Medical Home: Effects of Transformed Primary Care
Richard J. Gilfillan, MD; Janet Tomcavage, RN, MSN; Meredith B. Rosenthal, PhD; Duane E. Davis, MD; Jove Graham, PhD; Jason A. Roy, PhD; Steven B. Pierdon, MD; Frederick J. Bloom Jr, MD, MMM; Thomas R. Graf, MD; Roy Goldman, PhD, FSA; Karena M. Weikel, BA; Bruce H. Hamory, MD; Ronald A. Paulus, MD, MBA; and Glenn D. Steele Jr, MD, PhD
Insomnia Risks and Costs: Health, Safety, and Quality of Life
Mark R. Rosekind, PhD; and Kevin B. Gregory, BS
Effect of Inadequate Response to Treatment in Patients With Depression
Russell L. Knoth, PhD; Susan C. Bolge, PhD; Edward Kim, MD, MBA; and Quynh-Van Tran, PharmD
Using Search Engine Query Data to Track Pharmaceutical Utilization: A Study of Statins
Nathaniel M. Schuster, BS; Mary A.M. Rogers, PhD, MS; and Laurence F. McMahon Jr, MD, MPH
Employees' Willingness to Pay to Prevent Influenza
Stephen S. Johnston, MA; Matthew D. Rousculp, PhD, MPH; Liisa A. Palmer, PhD; Bong-Chul Chu, PhD; Parthiv J. Mahadevia, MD, MPH; and Kristin L. Nichol, MD, MPH, MBA
Currently Reading
Anticonvulsant Use After Formulary Status Change for Brand-Name Second-Generation Anticonvulsants
Hemal Patel, PharmD, MBA; Diana C. Toe, PharmD; Shawn Burke, RPh; and Rafia S. Rasu, PhD

Anticonvulsant Use After Formulary Status Change for Brand-Name Second-Generation Anticonvulsants

Hemal Patel, PharmD, MBA; Diana C. Toe, PharmD; Shawn Burke, RPh; and Rafia S. Rasu, PhD

The utilization pattern of anticonvulsants after a change in preferred-formulary coverage resulted in health plan savings of $0.16 per member per month.

Background: Anticonvulsant medications are commonly used for off-label indications. However, managed care organizations can restrict utilization of medication to indicated uses only.

 

Objective: To evaluate the pattern of off-label use of second-generation anticonvulsants after implementing a formulary change.

 

Methods: We did a retrospective analysis of an administrative pharmacy claims database for a managed care plan with more than 1 million members continuously enrolled during 2004-2005. The study evaluated off-label use and explored pharmacy utilization patterns (by physician specialty, region, plan type, age, sex, copayment) across the study population following the formulary change.

 

Results: A total of 10,185 patients had at least 1 pharmacy claim (total of 137,638 claims) for a second-generation anticonvulsant during the study period. Most members were female (68%), and 4.9% were <18 years old. A total of 3986 of 4698 patients (84.8%) and 4600 of 5487 patients (83.8%) had anticonvulsants prescribed for off-label use in 2004 and 2005, respectively (P = .162). The off-label usage pattern varied for individual anticonvulsants in 2004 and 2005 (P <.050), which may have been because of the change to nonpreferred coverage. Primary care physicians accounted for 41.3% of the prescribing of second-generation anticonvulsants for off-label uses, followed by neurologists (9.4%), psychiatrists (2.8%), and other (46.5%). The coverage change resulted in cost savings for the plan of $0.16 per member per month.

 

Conclusions: The off-label usage pattern varied for individual anticonvulsants in 2004 and 2005. Future considerations for controlling off-label use may include requiring prior authorization and provider education.

 

(Am J Manag Care. 2010;16(8):e197-e204)

A formulary change assigning brand-name second-generation anticonvulsants to nonformulary status and making generic gabapentin the only preferred anticonvulsant was implemented in January 2005 by a managed care plan.

 

  • In 2004 and 2005, respectively, 84.8% and 83.8% of anticonvulsants had off-label use (P =.162).
  • The off-label usage pattern varied for individual anticonvulsants in 2004 and 2005 (P <.050), which may have been because of the change to nonpreferred formulary status.
  • The health plan reported savings of $0.16 per member per month (PMPM): a decrease from $0.78 PMPM in 2004 to $0.62 PMPM in 2005.
Anticonvulsants belong to a group of drugs that control or prevent convulsions.1 Newer second-generation anticonvulsant agents have a well-documented beneficial effect as adjunctive treatment for those who suffer from seizure disorders. Besides being approved by the US Food and Drug Administration (FDA) to treat epilepsy, topiramate is approved for migraine prophylaxis, gabapentin for posttherapetic neuralgia, and lamotrigine for the treatment of bipolar disorder. First-generation anticonvulsants such as valproic acid, carbamazepine, and phenytoin are effective, but require closer monitoring, are dosed more frequently, and have a more serious side-effect profile than second-generation drugs such as gabapentin, lamotrigine, and levetiracetam. After review of a pooled analysis of placebo-controlled clinical studies in which these drugs were used to treat epilepsy as well as psychiatric disorders and other conditions, the FDA required manufacturers to include warnings about suicide risk with the use of these anticonvulsants.2

The approved FDA labeling summarizes safety and efficacy data obtained from clinical trials. Neurontin is the brand-name version of gabapentin; generic gabapentin was made available in the United States as of November 2004. Once a drug is approved by the FDA, physicians may prescribe the drug for any indication, without regard for the specific indication that was the basis for the FDA approval.3 Such off-label prescribing often raises questions regarding patient safety and healthcare costs. Managed care, however, can restrict utilization of medication to indicated uses only.

Stafford recently defined off-label prescribing as “the prescription of a medication in a manner different from that approved by the FDA.”4 A 2003 report showed that off-label use in the United States accounted for approximately 21% of prescriptions.5 An analysis of office-based physician prescribing showed that almost 1 of every 5 prescriptions in the United States in 2001 was prescribed for off-label use.6 Anticonvulsants account for the highest rates of off-label use (74%), followed by antipsychotics (60%) and antibiotics (41%).4,5 In the Georgia Medicaid population in 1999-2000, 71% of anticonvulsant use was for off-label purposes.7 In 2001, 83% of gabapentin use was off-label.6

Following the availability of generic gabapentin in November 2004, a managed care plan with 1,036,345 members implemented a formulary change in January 2005, assigning second-generation anticonvulsants to nonformulary status and making generic gabapentin the only preferred anticonvulsant drug (Figure 1). All members had a 3-tier benefit. Most typical copayments (±$5) were $10 (tier 1), $25 (tier 2), and $50 (tier 3). Copayments were not changed from 2004 to 2005 from a benefit perspective. The plan had a mandatory generic benefit design; therefore, members had to pay an ancillary charge to obtain Neurontin.

The primary objective of the present study was to evaluate the pattern of off-label use after the formulary change. To explore the variation in utilization after the change in pharmacy benefit design (a third-tier copayment for second-generation anticonvulsants, Figure 1), the secondary objective of this study was to explore the utilization pattern and costs of second-generation anticonvulsants after the formulary change.

METHODS

Study Design and Study Population

This study was a retrospective analysis using medical and pharmacy claims data from a large, national, managed care health plan of approximately 1 million commercially insured members with pharmacy benefits. The plan members were evenly distributed with a male to female ratio of 1:1. For the study, patients were selected who had at least 1 second-generation anticonvulsant pharmacy claim (topiramate, zonisamide, lamotrigine, gabapentin, tiagabine, or levetiracetam) during the study period (Figure 1). Pharmacy and medical claims were matched during the given year. Members with an anticonvulsant prescription were matched to their medical claims by International Classification of Diseases, Ninth Revision (ICD-9) codes and separated by labeled versus off-labeled indications. Those members who had an ICD-9 code for a labeled indication were grouped as “labeled” users. These patients had to be continuously enrolled from January 1, 2004, through December 31, 2005; there were no age criteria in patient selection.

Recruitment Strategy and Creation of Analytical Data Sets

Pharmacy claims data for this cohort were matched to medical claims data using unique member identification numbers. The medical claims data contained ICD-9, diagnosis (primary, secondary, and tertiary) codes of predetermined indicated and off-labeled uses. Labeled indications were derived from the product prescribing information. Off-label uses were obtained from the Micromedex Healthcare series database and abstracts of the Cochrane Collaborative Systemic Review.8,9 Key words used in the Cochrane Review search included [second generation anticonvulsants], [off-label use], [anti-epileptics], [gabapentin], [pain], [neuropathy], and [labeled indications]. These ICD-9 diagnosis codes for off-label uses were grouped into 7 categories, which included bipolar disorder, migraines, neuropathy, other mental disorders, other neurologic disorders, other pain, and miscellaneous. The Appendix lists all ICD-9 codes used to recognize off-label indications during the data extraction. Because topiramate has a migraine indication and lamotrigine has a bipolar disorder indication, those indications were not recorded as off-label uses. Physician specialty was identified as the primary description in the database of contracted providers with the plan. Noncontracted physicians whose information was not loaded into the database defaulted to the “other” category.

Statistical Analysis

Descriptive analyses for all variables were conducted for all study variables. The measured characteristics included age (at the beginning of the study), sex, and physician specialty. Patients’ baseline characteristics were identified from prescriptions filled during the year prior to implementing the benefit change (calendar year 2004). Bivariate comparisons of preimplementation versus postimplementation of the formulary change were conducted with t tests for continuous variables and χ2 tests for categorical variables. All statistical tests were considered significant at P <.05. All analyses for this study were conducted using SPSS version 11.0 (SPSS, Chicago, IL). Drug costs were measured as average wholesale price obtained from First Data Bank in February 200610; exact pharmacy claim costs were not used due to proprietary information held by the plan.

RESULTS

The final sample consisted of 10,185 patients with a total of 137,638 pharmacy claims. Table 1 shows patient characteristics, provider specialty, and patterns of anticonvulsant utilization in study population by year. Among those patients, 68.0% were female, whereas the health plan is evenly distributed with a male to female ratio of 1:1. Mean (SD) patient age was 46.75 (14.53) years; 4.9% were younger than age 18 years, 13.9% were age 18 to 35 years, 39.3% were age 36 to 50 years, 35.0% were age 51 to 65 years, and 7.0% were age >65 years. We found that more than 80% of anticonvulsant prescriptions were for off-label uses during the study period. In 2004 and 2005, respectively, 3986 of 4698 (84.8%) and 4600 of 5487 (83.8%) anticonvulsants had an off-label use (P = .162). The distribution of the second-generation anticonvulsant utilization during the study period is shown in Figure 2. There was an increase in overall utilization of gabapentin (68% to 72%) and lamotrigine (6% to 9%), and a decrease in utilization of topiramate (16% to 13%), tiagabine (4% to 2%), and zonisamide (3% to 1%) (Figure 2) (P <.05).

Off-label use of individual anticonvulsants varied (P <.050) after the change in preferred-formulary coverage (Table 2). Generic gabapentin utilization increased (11.5% to 68.0%), whereas topiramate utilization decreased (16.2% to 12.5%). Detailed utilization rates for each anticonvulsants are given in Table 2. Primary care providers accounted for 41.3% of the pharmacy claims for generation anticonvulsants for off-label uses versus 9.4% for neurologists, 2.8% for psychiatrists, and 46.5% for other specialty (Table 2). Only psychiatrists’ prescribing pattern changed with the formulary change during the study period (P = .001, Table 2). Most of these off-label uses were for pain other than neuropathy (22%) and for a miscellaneous category that included symptoms of involuntary movement, malnutrition, or injuries. Use of these agents to treat migraines decreased nonsignificantly between 2004 and 2005. Bipolar disorder–related off-label use decreased significantly from 2004 to 2005 (6.3% to 3.6%; P <.001). This study considered the use of topiramate for migraine prophylaxis, gabapentin for postherpetic neuralgia, and lamotrigine for bipolar disorder as labeled indications because these medications were FDA approved for those uses.

A noteworthy decrease in cost was noticed from the benefit change as the plan paid per member per month (PMPM) by $0.16 (PMPM $0.78 in 2004 to $0.62 in 2005). The number of anticonvulsant claims per patient remained the same for both years (Table 3).

DISCUSSION

We found that more than 80% of anticonvulsant prescriptions were for off-label purposes. Most of these uses were for pain, neuropathic pain, and other mental and neurologic disorders, which is consistent with the study of off-label anticonvulsant use in the Georgia Medicaid population.8 Several studies reported that 71% to 74% of these anticonvulsants claims were being used for off-label indications.3,4,7,11 Since this study, there have been regulatory changes that allow off-label promotion to physicians. Allowing promotion of drugs for off-label uses without evidence to support their safety and efficacy for these purposes may lead to additional costs and unknown outcomes.12

Changing the formulary by removing selected second-generation anticonvulsants, which resulted in a mean $25 increase in member copayment, was not associated with a significant change in overall rates of off-label prescribing. However, the usage patterns for individual anticonvulsants changed among off-label users (P <.050), which may have been because of the change in the formulary plan. Utilization of individual anticonvulsants both decreased and increased. In this managed care plan only psychiatrists prescribed anticonvulsants at a significantly lower rate after the formulary change (3.3% vs 2.2%; P = .001).

In this study population, gabapentin was utilized most frequently for off-label purposes (70.1%) compared with levetiracetam (3.1%), tiagabine (2.5%), and zonisamide (2.0%) (Table 2). The 2005 change in gabapentin utilization was probably due to the availability of gabapentin at the lowest-tier copayment (standard generic copayment of $10 per prescription) in 2005. Gabapentin became available in a generic form in November 2004. More investigation is needed to examine the reason of this utilization pattern.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up